Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Enveric Biosciences Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Enveric Biosciences Inc trades at $1.34 (market cap $5.44M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7332.7× Enveric Biosciences Inc's market cap, and Alnylam Pharmaceuticals, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ALNY | ENVB | |
|---|---|---|
Market Cap | $39.89B | $5.44M |
Sector | Health | Health |
52-Week High | $491.22 | $17.40 |
52-Week Low | $278.09 | $1.28 |
Enterprise Value | $38.15B | $529.67K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
